0000000000085490

AUTHOR

Marcello Moccia

showing 12 related works from this author

A multicenter survey on access to care in Multiple Sclerosis-related trigeminal neuralgia

2021

The prevalence of trigeminal neuralgia (TN) in patients with Multiple Sclerosis (MS) is higher than in the general population and its management can be particularly challenging due to a number of reasons including high recurrence rates, lack of MS-specific treatment guidelines and uncertainties about pain pathophysiology. Aim of this cross-sectional, multicentre survey was to gather information on the current treatment modalities and options of MS-related TN across 23 Italian MS centres. Initial medical management (carbamazepine or oxcarbazepine) of MS-related TN was fairly homogeneous throughout Italian centres. The most commonly available surgical procedure was microvascular decompression…

medicine.medical_specialtyMultiple Sclerosismultiple sclerosis; trigeminal neuralgiaCross-sectional studymedicine.medical_treatmentPopulationMicrovascular decompressionHealth Services Accessibility03 medical and health sciences0302 clinical medicineRetrospective StudieTrigeminal neuralgiaMultiple SclerosimedicineHumans030212 general & internal medicineIntensive care medicineeducationOxcarbazepineRetrospective StudiesCross-Sectional Studieeducation.field_of_studybusiness.industryMultiple sclerosisRetrospective cohort studyTrigeminal Neuralgiamedicine.diseaseCross-Sectional StudiesTreatment OutcomeItalyNeurologyMulticenter surveyNeurology (clinical)businessMultiple Sclerosis; Trigeminal neuralgia; Cross-Sectional Studies; Health Services Accessibility; Humans; Italy; Retrospective Studies; Treatment Outcome; Multiple Sclerosis; Trigeminal NeuralgiaTrigeminal neuralgia030217 neurology & neurosurgeryHumanmedicine.drugJournal of the Neurological Sciences
researchProduct

Editorial: Pathophysiologic Insights From Biomarker Studies in Neurological Disorders

2020

business.industryneurodegenerationneuroimmunologyBioinformaticslcsh:RC346-429PathophysiologyEditorialNeuroimmunologyNeurologybiomarkerBiomarker (medicine)MedicineNeurology (clinical)pathomechanismbusinesslcsh:Neurology. Diseases of the nervous systempathophysiologyFrontiers in Neurology
researchProduct

Disability assessment using Google Maps.

2021

Objectives To evaluate the concordance between Google Maps® application (GM®) and clinical practice measurements of ambulatory function (e.g., Ambulation Score (AS) and respective Expanded Disability Status Scale (EDSS)) in people with multiple sclerosis (pwMS). Materials and methods This is a cross-sectional multicenter study. AS and EDSS were calculated using GM® and routine clinical methods; the correspondence between the two methods was assessed. A multinomial logistic model is investigated which demographic (age, sex) and clinical features (e.g., disease subtype, fatigue, depression) might have influenced discrepancies between the two methods. Results Two hundred forty-three pwMS were …

medicine.medical_specialtyNeurologyMultiple SclerosisConcordanceAmbulatory disordersDermatology03 medical and health sciencesDisability Evaluation0302 clinical medicineInternal medicinemedicineGoogle MapsHumans030212 general & internal medicineDepression (differential diagnoses)Ambulatory disorderFatigueNeuroradiologyExpanded Disability Status Scalebusiness.industryGeneral MedicineOdds ratioConfidence intervalSearch EnginePsychiatry and Mental healthCross-Sectional StudiesAmbulatorye-HealthOriginal ArticleNeurology (clinical)businessDigital health030217 neurology & neurosurgeryNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical NeurophysiologyReferences
researchProduct

mRNA COVID-19 vaccines do not increase the short-term risk of clinical relapses in multiple sclerosis

2021

Multiple sclerosis (MS) is a chronic, immune-mediated disorder of the central nervous system. A novel coronavirus, namely SARS-CoV-2, has been recently responsible for the highly infectious disease referred as COVID-19, rapidly spreading all over the world. Many vaccines have been developed to control COVID-19 pandemic, including the mRNA vaccines Pfizer/BioNTech (BNT162b2) and Moderna (mRNA1273).1 The vaccination of people with MS (pwMS) has been recommended by several national and international MS societies. However, effectiveness and safety of anti-COVID-19 mRNA vaccines in MS need to be confirmed. The aim of this study was to evaluate the short-term risk of clinical relapses in pwMS in …

Pediatricsmedicine.medical_specialtyeducation.field_of_studyExpanded Disability Status ScaleCoronavirus disease 2019 (COVID-19)business.industryMultiple sclerosisCOVID-19; multiple sclerosis; neuroimmunologyPopulationCOVID-19neuroimmunologymedicine.diseasemultiple sclerosisVaccinationPsychiatry and Mental healthInfectious disease (medical specialty)multiple sclerosiPandemicmedicineSurgeryObservational studymultiple sclerosis neuroimmunology COVID-19Neurology (clinical)businesseducation
researchProduct

Harmonization of real-world studies in multiple sclerosis: Retrospective analysis from the rirems group

2020

Background: Worldwide multiple sclerosis (MS) centers have coordinated their efforts to use data acquired in clinical practice for real-world observational studies. In this retrospective study, we aim to harmonize outcome measures, and to evaluate their heterogeneity within the Rising Italian Researchers in MS (RIReMS) study group. Methods: RIReMS members filled in a structured questionnaire evaluating the use of different outcome measures in clinical practice. Thereafter, thirty-four already-published papers from RIReMS centers were used for heterogeneity analyses, using the DerSimonian and Laird random-effects method to compute the between-study variance (τ2). Results: Based on questionna…

AdultLongitudinal studymedicine.medical_specialtyHarmonizationOutcome measuresMultiple sclerosisOutcome measure03 medical and health sciences0302 clinical medicineHarmonization; Multiple sclerosis; Outcome measures; Real worldmedicineHumansMultiple sclerosi030212 general & internal medicineAge of OnsetAgedRetrospective StudiesExpanded Disability Status Scalebusiness.industryMultiple sclerosisOutcome measuresRetrospective cohort studyReal worldGeneral MedicineVariance (accounting)medicine.diseaseNeurologyItalyHarmonizationFamily medicineObservational studyFemaleNeurology (clinical)business030217 neurology & neurosurgeryHarmonization; Multiple sclerosis; Outcome measures; Real world; Adult; Age of Onset; Aged; Female; Humans; Italy; Retrospective Studies; Multiple Sclerosis
researchProduct

Characteristics and treatment of Multiple Sclerosis-related trigeminal neuralgia: An Italian multi-centre study

2019

Abstract Background The prevalence of trigeminal neuralgia (TN) in Multiple Sclerosis (MS) patients is higher than in the general population and its management can be particularly challenging. Our aim is to describe the characteristics, treatment and prognostic factors of MS-related TN in a retrospective multicentre study. Methods Neurologists members of the RIREMS group (Rising Researchers in MS) enrolled MS patients with a TN diagnosis and filled out a spreadsheet comprising their clinical data. Results Population consisted of 298 patients. First-choice preventive treatments were carbamazepine and oxcarbazepine. A surgical procedure was performed in 81 (30%) patients, most commonly gamma …

Pediatricsmedicine.medical_treatmentmultiple sclerosismicrovascular decompression surgerytime factors0302 clinical medicineRadiofrequency thermocoagulationTrigeminal neuralgiaMultiple SclerosiOutcome Assessment Health Careitalymiddle agedpain030212 general & internal medicineOxcarbazepinehumanseducation.field_of_studytrigeminal neuralgiaadultDisability; Multiple Sclerosis; Pain; Trigeminal neuralgiaradiosurgeryGeneral MedicineAnalgesics Non-Narcotichealth carefollow-up studiesSettore MED/26 - NEUROLOGIAagedretrospective studiesfemaleNeurologydisability; multiple sclerosis; pain; trigeminal neuralgia; adult; aged; analgesics non-narcotic; female; follow-up studies; humans; italy; male; microvascular decompression surgery; middle aged; multiple sclerosis; radiosurgery; retrospective studies; severity of illness index; sex factors; time factors; trigeminal neuralgia; neurosurgical procedures; outcome assessment health careanalgesicsTrigeminal neuralgiamedicine.drugmedicine.medical_specialtyMultiple SclerosisPopulationPainMicrovascular decompression03 medical and health sciencesmalemedicineseverity of illness indexeducationoutcome assessmentDisabilitybusiness.industryMultiple sclerosisCarbamazepinemedicine.diseaseneurosurgical proceduresDiscontinuationsex factorsdisabilitynon-narcoticNeurology (clinical)business030217 neurology & neurosurgery
researchProduct

A multicentRE observational analysiS of PErsistenCe to Treatment in the new multiple sclerosis era: the RESPECT study.

2018

In this independent, multicenter, retrospective study, we investigated the short-term persistence to treatment with first-line self-injectable or oral disease-modifying treatments (DMTs) in patients with relapsing–remitting multiple sclerosis. Data of patients regularly attending 21 Italian MS Centres who started a self-injectable or an oral DMT in 2015 were collected to: (1) estimate the proportion of patients discontinuing the treatment; (3) explore reasons for discontinuation; (3) identify baseline predictors of treatment discontinuation over a follow-up period of 12 months. We analyzed data of 1832 consecutive patients (1289 women, 543 men); 374 (20.4%) of them discontinued the prescrib…

MaleInjectionTime FactorsPatient Dropoutdisease-modifying therapies; multiple sclerosis; outcome measurement; persistence to treatment; quality of lifeAdministration OralSelf AdministrationSex FactorKaplan-Meier EstimateRelapsing-Remittingmultiple sclerosisImmunologic Factor0302 clinical medicineQuality of lifeRetrospective StudieRisk FactorsMedicine030212 general & internal medicineDisease-modifying therapiedisease-modifying therapiesDisease-modifying therapies Multiple sclerosis Outcome measurement Persistence to treatment Quality of life Administration Oral Adult; Female Follow-Up Studies Humans Immunologic Factors Injections Kaplan-Meier EstimateMale Multiple Sclerosis Relapsing-Remitting Patient Dropouts Prognosis Proportional Hazards Models Retrospective Studies Risk Factors Self Administration Sex Factors Time FactorsHazard ratioPrognosisNeurologyTolerabilityAdministrationSettore MED/26 - NeurologiaFemaleoutcome measurementHumanOralAdultmedicine.medical_specialtyPatient DropoutsTime FactorPrognosiFollow-Up StudieInjections03 medical and health sciencesRoute of administrationMultiple Sclerosis Relapsing-RemittingSex FactorsInternal medicineHumansImmunologic FactorsMultiple sclerosiAdverse effectProportional Hazards ModelsRetrospective Studiesbusiness.industryProportional hazards modelRisk FactorRetrospective cohort studyDiscontinuationDisease-modifying therapies; Multiple sclerosis; Outcome measurement; Persistence to treatment; Quality of life; Administration Oral; Adult; Female; Follow-Up Studies; Humans; Immunologic Factors; Injections; Kaplan-Meier Estimate; Male; Multiple Sclerosis Relapsing-Remitting; Patient Dropouts; Prognosis; Proportional Hazards Models; Retrospective Studies; Risk Factors; Self Administration; Sex Factors; Time Factorsquality of lifeProportional Hazards Modelpersistence to treatmentNeurology (clinical)business030217 neurology & neurosurgeryFollow-Up StudiesJournal of neurology
researchProduct

Defining the course of tumefactive multiple sclerosis: A large retrospective multicentre study

2021

Background and purpose: Tumefactive multiple sclerosis (TuMS) (i.e., MS onset presenting with tumefactive demyelinating lesions [TDLs]) is a diagnostic and therapeutic challenge. We performed a multicentre retrospective study to describe the clinical characteristics and the prognostic factors of TuMS. Methods: One hundred two TuMS patients were included in this retrospective study. Demographic, clinical, magnetic resonance imaging (MRI), laboratory data and treatment choices were collected. Results: TuMS was found to affect women more than men (female:male: 2.4), with a young adulthood onset (median age: 29.5 years, range: 11–68 years, interquartile range [IQR]: 38 years). At onset, 52% of …

Maletumefactive demyelinating lesions (TDLs)0302 clinical medicineRetrospective StudieInterquartile rangedifferential diagnosis030212 general & internal medicineProspective StudiesYoung adultProspective cohort studyChildtreatmentTumefactive multiple sclerosiTumefactive demyelinating lesionsDemyelinating DiseaseMiddle AgedMagnetic Resonance ImagingDifferential diagnosis Multiple sclerosis Tumefactive demyelinating lesions Tumefactive multiple sclerosisNeurologydifferential diagnosis; Multiple sclerosis; Tumefactive demyelinating lesions; Tumefactive multiple sclerosisFemaleHumanAdultmedicine.medical_specialtyMultiple SclerosisAdolescentdifferential diagnosiSettore MED/26Multiple sclerosis03 medical and health sciencesYoung AdultTumefactive multiple sclerosisOligoclonal BandInternal medicinemedicineHumansMultiple sclerosiTumefactive multiple sclerosisTumefactive multiple sclerosis (TuMS)AgedRetrospective StudiesTumefactive demyelinating lesionExpanded Disability Status Scalebusiness.industryOligoclonal BandsRetrospective cohort studyOdds ratiomedicine.diseaseConfidence intervalProspective Studiedifferential diagnosis; Multiple sclerosis; Tumefactive demyelinating lesions; Tumefactive multiple sclerosis; Adolescent; Adult; Aged; Child; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Oligoclonal Bands; Prospective Studies; Retrospective Studies; Young Adult; Demyelinating Diseases; Multiple SclerosisprognosisNeurology (clinical)business030217 neurology & neurosurgeryDemyelinating Diseases
researchProduct

Global investments in pandemic preparedness and COVID-19: development assistance and domestic spending on health between 1990 and 2026

2023

Background The COVID-19 pandemic highlighted gaps in health surveillance systems, disease prevention, and treatment globally. Among the many factors that might have led to these gaps is the issue of the financing of national health systems, especially in low-income and middle-income countries (LMICs), as well as a robust global system for pandemic preparedness. We aimed to provide a comparative assessment of global health spending at the onset of the pandemic; characterise the amount of development assistance for pandemic preparedness and response disbursed in the first 2 years of the COVID-19 pandemic; and examine expectations for future health spending and put into context the expected ne…

coordinationcommunicationoutbreak responseCOVID-19 GBDresponse planPublic Health Global Health Social Medicine and EpidemiologyGeneral Medicinecontact managementpandemic Covid 19financingepidemic alertepidemiological investigationFolkhälsovetenskap global hälsa socialmedicin och epidemiologiinternational health regulationsurveillanceGlobal burden diseasefinancing; global spending; pandemic Covid 19;global spendingpreparedne
researchProduct

Informing MS patients on treatment options: a consensus on the process of consent taking

2020

Abstract\ud In the last years, change in multiple sclerosis (MS) therapeutic scenario has highlighted the need for an improved doctor-patient communication in advance of treatment initiation in order to allow patient’s empowerment in the decision-making process.\ud Aims\ud The aims of our project were to review the strategies used by Italian MS specialists to inform patients about treatment options and to design a multicentre shared document that homogenizes the information about disease-modifying treatment (DMTs) and the procedure of taking informed consent in clinical practice.\ud Results\ud The new resource, obtained by consensus among 31 neurologists from 27 MS Centres in Italy with the…

medicine.medical_specialtyConsensusProcess (engineering)media_common.quotation_subjectDermatologyDisease modifying treatment; Informed consent; Multiple sclerosisMultiple sclerosis03 medical and health sciences0302 clinical medicineResource (project management)Informed consentDisease modifying treatmentmedicineHumans030212 general & internal medicineInformed consentEmpowermentmedia_commonPhysician-Patient Relationsbusiness.industryTreatment optionsGeneral MedicineClinical PracticePsychiatry and Mental healthItalyFamily medicineDisease modifying treatment; Informed consent; Multiple sclerosis; Consensus; Humans; Italy; Physician-Patient Relations; Informed Consent; Multiple SclerosisSettore MED/26 - NeurologiaNeurology (clinical)Decision processbusiness030217 neurology & neurosurgery
researchProduct

Population-level risks of alcohol consumption by amount, geography, age, sex, and year: a systematic analysis for the Global Burden of Disease Study …

2022

Background: The health risks associated with moderate alcohol consumption continue to be debated. Small amounts of alcohol might lower the risk of some health outcomes but increase the risk of others, suggesting that the overall risk depends, in part, on background disease rates, which vary by region, age, sex, and year. Methods: For this analysis, we constructed burden-weighted dose-response relative risk curves across 22 health outcomes to estimate the theoretical minimum risk exposure level (TMREL) and non-drinker equivalence (NDE), the consumption level at which the health risk is equivalent to that of a non-drinker, using disease rates from the Global Burden of Diseases, Injuries, and …

AdultMaleAlcohol DrinkingCONTROL POLICIESadult; Alcohol Drinking; Child Preschool; Female; Geography; Global Burden of Disease; Global Health; Humans; Male; Middle Aged; Quality-Adjusted Life Years; Risk FactorsNDASALL-CAUSEGUIDELINESGlobal HealthGBD 2020 Alcohol CollaboratorsGlobal Burden of DiseaseCOST-EFFECTIVENESSMedicine General & InternalDRINKINGSDG 3 - Good Health and Well-beingRA0421Risk FactorsGeneral & Internal MedicineQuality-Adjusted Life YearRA0421 Public health. Hygiene. Preventive MedicineDRINKERSHumansChildPreschool11 Medical and Health SciencesMETAANALYSISMCCScience & Technologyglobal burden of diseaseGeographyRisk FactoradultGeneral MedicineMiddle AgedCANCERalcohol drinkingACChild Preschool3121 General medicine internal medicine and other clinical medicineFemaleQuality-Adjusted Life YearsREDUCED MORTALITYLife Sciences & Biomedicinealcohol drinking; global burden of disease; adultHuman
researchProduct

Burden of non-communicable diseases among adolescents aged 10-24 years in the EU, 1990-2019: a systematic analysis of the Global Burden of Diseases S…

2022

Background: Disability and mortality burden of non-communicable diseases (NCDs) have risen worldwide; however, the NCD burden among adolescents remains poorly described in the EU. Methods: Estimates were retrieved from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019. Causes of NCDs were analysed at three different levels of the GBD 2019 hierarchy, for which mortality, years of life lost (YLLs), years lived with disability (YLDs), and disability-adjusted life-years (DALYs) were extracted. Estimates, with the 95% uncertainty intervals (UI), were retrieved for EU Member States from 1990 to 2019, three age subgroups (10–14 years, 15–19 years, and 20–…

Malemortality burdenAdolescentRJRJ101CareGlobal Burden of DiseaseLife ExpectancyRJ101 Child Health. Child health servicesSDG 3 - Good Health and Well-beingRA04213123 Gynaecology and paediatricsRisk FactorsRA0421 Public health. Hygiene. Preventive MedicineDevelopmental and Educational PsychologyHumansDisabled PersonsNoncommunicable DiseasesFutureDeterminantsMCCDisabilityPublic Health Global Health Social Medicine and EpidemiologyBurden of non-communicable diseases among adolescents aged 10–24 years in the EU 1990–2019: a systematic analysis of the Global Burden of Diseases Study 20193rd-DASDisability; mortality burdenFolkhälsovetenskap global hälsa socialmedicin och epidemiologin/aHealthPediatrics Perinatology and Child HealthFemaleRA
researchProduct